ClinicalTrials.gg
CompletedNCT07266207Updated Dec 5, 2025

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis

A Phase 1 interventional study of ARD-885 Tablets and ARD-885 Placebo Tablet in Rheumatoid Arthritis (RA), sponsored by Artivila (Shenzhen) Innovation Center, Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Artivila (Shenzhen) Innovation Center, Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Dec 2024, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Enrollment
129th of 217
94 · median 134
Started
2024
with 9 others
Phase 1
54 of 249
20 open now
Registered
226th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 129th largest by enrollment of the 217 interventional ones that give a count, is one of 10 that started in 2024, is one of 54 in phase 1, and was the 226th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

The proposed study is a randomized, double-blind, placebo-controlled single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetic, and food effects of ARD-885 Film-coated Tablets in healthy subjects.The entire study includes 3 parts: a single ascending dose study, a multiple ascending dose study, and a food-effect bioavailability study in healthy subjects.

Read the detailed description

The whole study includes 3 parts: a single ascending dose study, a multiple ascending dose study, and a food-effect bioavailability study. The SAD and MAD studies are randomized, double-blinded, and placebo-controlled studies, and the FE study is a randomized, open-label, two-period, two-treatment (2×2) crossover study.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects:

    1. Healthy male and female subjects of any ethnic origin between the ages of 18 and 55. Male and female patients with rheumatoid arthritis between the ages of 18 and 70.
    2. An document signed and dated by the subject. Subjects must be willing to understand and comply with all research procedures and restrictions and be able to communicate effectively with investigators.
    3. A minimum body weight of 50 kg for males and 45 kg for females, with a of 18 to 28 kg/m2 for healthy subjects and 18 to 35 kg/m2 for patients with RA.
    4. Subject (including partner) agrees to use at least one effective method during sexual activity with partner from screening until 3 months after dosing agrees not to participate in sperm or egg donation during the study period until 3 months after the last dosing. See Section 8.1 for specific contraceptive methods.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to any component of ARD-885 Film-coated Tablets, or individuals with a to allergies (multiple drug and food allergies), as determined by the investigator, and deemed unsuitable for inclusion.
  2. Lactating women; Women of reproductive age with menstrual disorders within 90 days before administration; Women of childbearing age who have had unprotected sexual intercourse with an opposite-sex partner in the 28 days before administration. Female subjects who are lactating or have a positive serum pregnancy result during the screening period or during the trial.
  3. Participated in any drug clinical trial within 90 days before administration, or the administration date of this study is still within the safety specified in the previous drug clinical trial.
  4. Non-physiological blood loss ≥ 200 ml within 60 days before administration (including trauma, blood collection, blood donation); Or plan to donate blood during the trial or within 30 days of administration.
  5. Had a major disease that investigators considered within 90 days before first administration; Have any active or history of malignancy in the 5 years prior to screening, with the exception of treated and considered cured skin squamous or basal cell carcinoma, cervical carcinoma in situ, or breast ductal carcinoma in situ.
  6. Had major surgery within 60 days of administration, or had any surgery within 28 days of administration.
  7. Infectious diseases such like fever and so on within 28 days before administration.
  8. Previous use of any of the drugs or treatments listed in protocol.
  9. Received vaccine or within 1 month before administration, or who plan to receive the vaccine during the trial period.
  10. Those who smoked more than 5 pieces of tobacco or equivalent daily in the 3 months before screening, or drank ≥ 14 units of alcohol per week; Or disagree with the prohibition of smoking or alcohol during the trial; Or positive alcohol serum test during screening or baseline (Day-1).
  11. Those who test positive for urine drugs or have a history of drug abuse or use of drugs in the past five years.
  12. +Positive for Treponema pallidum antibodies, surface antigen, hepatitis B core antibodies, virus antibodies or antibodies.
  13. Those who is diagnosed as tuberculosis or have a history of non-tuberculous mycobacterial infections
  14. Have a serious disease of the blood system or any disease that can cause hemolysis or instability of red blood cells, such as malaria, hemolytic anemia, etc..
  15. At the time of screening, clinically significant gastrointestinal, liver or kidney abnormalities known abnormal which likely to affect drug intake, transport, absorption, distribution, metabolism or excretion.
  16. Ingested any food or beverage containing caffein, or other xanthine-rich food or food that can induce or inhibit liver metabolic enzymes and beverages made from it within 48 hours before taking the study drug, or food or beverages containing alcohol, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.
  17. Those who Can not tolerate venous puncture blood collection or faint blood needle.
  18. Has special requirements for diet and cannot comply with a unified diet.
  19. By the investigator's decision, other factors may affect the study results and interfere with his/her participation in the study process.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    ARD-885 Tablets (Multiple Administration Dose, cohort B1~B3)

    ARD-885 Tablets, 25 mg/50 mg/100 mg, once a day(QD), from Day1\~Day7

    Drug: ARD-885 Tablets

  • Experimental
    ARD-885 tablet (Single Administration Dose, cohort A0~A7)

    ARD-885 Tablets, 5/10/30/60/100/150/200/250 mg,a single dose on Day1

    Drug: ARD-885 Tablets

  • Placebo comparator
    ARD-885 Placebo tablet (Single Ascending Dose, cohort A1~A7)

    ARD-885 Placebo tablet, a single dose on Day1

    Drug: ARD-885 Placebo Tablet

  • Experimental
    ARD-885 Tablets (Food Effect, cohort C1~C2)

    ARD-885 tablets, 50mg, a single dose on Day1 and Day7, fed or fasted crossover

    Drug: ARD-885 Tablets

  • Placebo comparator
    ARD-885 Placebo Tablets (Multiple Administration Dose, cohort B1~B3)

    ARD-885 Placebo tablets, once a day(QD), from Day1\~Day7

    Drug: ARD-885 Placebo Tablet

Interventions

  • DrugARD-885 Tablets

    ARD-885 Tablet is a dual-target inhibitor of IRAK4 and IRAK1.

  • DrugARD-885 Placebo Tablet

    Placebo Tablet to ARD-885 tablets.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)/Severe Adverse Events (SAE)

    Safety and tolerability are assessed by the incidence of adverse events and its severity caused by the study drug during or after dose.

    Time frame: The first day of the first administration until 7 days after the last administration.

Secondary outcomes

  1. PK: Cmax of ARD-885.

    Pharmacokinetics (PK): Maximum observed concentration.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  2. PK: T1/2 of ARD-885.

    Pharmacokinetics (PK): Apparent terminal elimination half-life.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  3. PK: Tmax of ARD-885.

    Pharmacokinetics (PK): Time to reach Cmax. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  4. PK: AUC0-t of ARD-885.

    Pharmacokinetics (PK): The area under the plasma concentration-time curve from time 0 to concentration time.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  5. PK: AUC0-last of ARD-885.

    Pharmacokinetics (PK): The area under the plasma concentration-time curve, from time 0 to the last measurable non-zero concentration.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  6. PK: AUC0-inf of ARD-885.

    Pharmacokinetics (PK): The area under the plasma concentration-time curve from time 0 extrapolated to infinity.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  7. PK: CL/F of ARD-885.

    Pharmacokinetics (PK): Apparent oral drug clearance.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  8. PK: Css_max of ARD-885.

    Pharmacokinetics (PK): Steady-state maximum blood concentration in MAD study.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  9. PK: Css_min of ARD-885.

    Pharmacokinetics (PK): Steady-state minimum blood concentration in MAD study.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  10. PK: Tss_max of ARD-885.

    Pharmacokinetics (PK): Time to reach Cmax at steady state in MAD study.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  11. PK: AUCss_tau of ARD-885.

    Pharmacokinetics (PK): The area under the concentration-time curve at one dosing interval after reaching a steady state in MAD study.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  12. PK: RACmax of ARD-885.

    Pharmacokinetics (PK): Accumulation ratio on Cmax of ARD-885 in MAD study.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  13. PK: RAAUCtau of ARD-885

    Pharmacokinetics (PK): Accumulation ratio on AUCtau in MAD study.

    Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.

  14. PD: The concentration of TNF-α

    TNF-α, IL-1β and IL-6 are a pro-inflammatory cytokines whose high expression indicating the activation of TLRs/IL-1R/NF-κB signaling pathway. Healthy Subjects in MAD study(B1\~B3) will have their blood samples collected to detect levels of inflammatory factors TNF-α, IL-1β and IL-6 expression.

    Time frame: blood samples were collected from 1 hour before first administration to 24 hours after the last administration.

  15. PD: The concentration of IL-6.

    TNF-α, IL-1β and IL-6 are a pro-inflammatory cytokines whose high expression indicating the activation of TLRs/IL-1R/NF-κB signaling pathway. Healthy Subjects in MAD study(B1\~B3) will have their blood samples collected to detect levels of inflammatory factors TNF-α, IL-1β and IL-6 expression.

    Time frame: blood samples were collected from 1 hour before first administration to 24 hours after the last administration.

  16. PD: The concentration of IL-1β.

    TNF-α, IL-1β and IL-6 are a pro-inflammatory cytokines whose high expression indicating the activation of TLRs/IL-1R/NF-κB signaling pathway. Healthy Subjects in MAD study(B1\~B3) will have their blood samples collected to detect levels of inflammatory factors TNF-α, IL-1β and IL-6 expression.

    Time frame: blood samples were collected from 1 hour before first administration to 24 hours after the last administration.

07

Study locations

1 site
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Aug 2025, 7 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 7 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Dec 5, 2025
StartActual
Dec 16, 2024
Primary completionActual
Aug 14, 2025
CompletionActual
Aug 18, 2025
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07266207
Lead sponsor
Artivila (Shenzhen) Innovation Center, Ltd
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Dec 16, 2024
Primary completion
Aug 14, 2025
Completion
Aug 18, 2025
Last update
Dec 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion